Peter R. Hoffmann to Disease Progression
This is a "connection" page, showing publications Peter R. Hoffmann has written about Disease Progression.
Connection Strength
0.233
-
Marciel MP, Rose AH, Martinez V, Horio DT, Hashimoto AS, Hoffmann FW, Bertino P, Hoffmann PR. Calpain-2 inhibitor treatment preferentially reduces tumor progression for human colon cancer cells expressing highest levels of this enzyme. Cancer Med. 2018 01; 7(1):175-183.
Score: 0.114
-
Rose AH, Bertino P, Hoffmann FW, Gaudino G, Carbone M, Hoffmann PR. Increasing dietary selenium elevates reducing capacity and ERK activation associated with accelerated progression of select mesothelioma tumors. Am J Pathol. 2014 Apr; 184(4):1041-1049.
Score: 0.087
-
Chatterjee S, Lee LY, Kawahara R, Abrahams JL, Adamczyk B, Anugraham M, Ashwood C, Sumer-Bayraktar Z, Briggs MT, Chik JHL, Everest-Dass A, F?rster S, Hinneburg H, Leite KRM, Loke I, M?ginger U, Moh ESX, Nakano M, Recuero S, Sethi MK, Srougi M, Stavenhagen K, Venkatakrishnan V, Wongtrakul-Kish K, Diestel S, Hoffmann P, Karlsson NG, Kolarich D, Molloy MP, Muders MH, Oehler MK, Packer NH, Palmisano G, Thaysen-Andersen M. Protein Paucimannosylation Is an Enriched N-Glycosylation Signature of Human Cancers. Proteomics. 2019 11; 19(21-22):e1900010.
Score: 0.032